These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 8722291)

  • 1. Synergistic inhibitory effect of enviroxime and disoxaril on poliovirus type 1 replication.
    Nikolaeva L; Galabov AS
    Acta Virol; 1995 Dec; 39(5-6):235-41. PubMed ID: 8722291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro inhibitory effects of dual combinations of picornavirus replication inhibitors.
    Nikolaeva L; Galabov AS
    Acta Virol; 1999 Oct; 43(5):303-11. PubMed ID: 10757231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytotoxicity of the synergistic antienteroviral combination of enviroxime and disoxaril.
    Nikolaeva L; Galabov AS
    Acta Virol; 1999 Aug; 43(4):263-5. PubMed ID: 10749374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiviral effect of the combination of enviroxime and disoxaril on coxsackievirus B1 infection.
    Nikolaeva L; Galabov AS
    Acta Virol; 2000 Apr; 44(2):73-8. PubMed ID: 10989697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic drug combinations against the in vitro replication of Coxsackie B1 virus.
    Nikolaeva-Glomb L; Galabov AS
    Antiviral Res; 2004 Apr; 62(1):9-19. PubMed ID: 15026197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of poliovirus uncoating by disoxaril (WIN 51711).
    Zeichhardt H; Otto MJ; McKinlay MA; Willingmann P; Habermehl KO
    Virology; 1987 Sep; 160(1):281-5. PubMed ID: 2820136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The antiviral compound enviroxime targets the 3A coding region of rhinovirus and poliovirus.
    Heinz BA; Vance LM
    J Virol; 1995 Jul; 69(7):4189-97. PubMed ID: 7769678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro assembly of poliovirus 14 S subunits: disoxaril stabilization as a model for the antigenicity conferring activity of infected cell extracts.
    Rombaut B; Boeyé A
    Virology; 1991 Feb; 180(2):788-92. PubMed ID: 1703372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphatidylinositol 4-kinase III beta is a target of enviroxime-like compounds for antipoliovirus activity.
    Arita M; Kojima H; Nagano T; Okabe T; Wakita T; Shimizu H
    J Virol; 2011 Mar; 85(5):2364-72. PubMed ID: 21177810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cellular kinase inhibitors that suppress enterovirus replication have a conserved target in viral protein 3A similar to that of enviroxime.
    Arita M; Wakita T; Shimizu H
    J Gen Virol; 2009 Aug; 90(Pt 8):1869-1879. PubMed ID: 19439558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A bifunctional anti-enterovirus compound that inhibits replication and the early stage of enterovirus 71 infection.
    Arita M; Takebe Y; Wakita T; Shimizu H
    J Gen Virol; 2010 Nov; 91(Pt 11):2734-44. PubMed ID: 20660150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis, antiviral activity, and biological properties of vinylacetylene analogs of enviroxime.
    Victor F; Brown TJ; Campanale K; Heinz BA; Shipley LA; Su KS; Tang J; Vance LM; Spitzer WA
    J Med Chem; 1997 May; 40(10):1511-8. PubMed ID: 9154972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disoxaril mutants of Coxsackievirus B1: phenotypic characteristics and analysis of the target VP1 gene.
    Nikolova I; Galabov AS; Petkova R; Chakarov S; Atanasov B
    Z Naturforsch C J Biosci; 2011; 66(11-12):627-36. PubMed ID: 22351989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and antiviral activity of C2 analogs of enviroxime: an exploration of the role of critical functionality.
    Victor F; Loncharich R; Tang J; Spitzer WA
    J Med Chem; 1997 Oct; 40(21):3478-83. PubMed ID: 9341923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. R75761, a lead compound for the development of antiviral drugs in late stage poliomyelitis eradication strategies and beyond.
    Thys B; De Palma AM; Neyts J; Andries K; Vrijsen R; Rombaut B
    Antiviral Res; 2008 Jun; 78(3):278-81. PubMed ID: 18294707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence that enviroxime targets multiple components of the rhinovirus 14 replication complex.
    Brown-Augsburger P; Vance LM; Malcolm SK; Hsiung H; Smith DP; Heinz BA
    Arch Virol; 1999; 144(8):1569-85. PubMed ID: 10486111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutations in the 2C region of poliovirus responsible for altered sensitivity to benzimidazole derivatives.
    Shimizu H; Agoh M; Agoh Y; Yoshida H; Yoshii K; Yoneyama T; Hagiwara A; Miyamura T
    J Virol; 2000 May; 74(9):4146-54. PubMed ID: 10756027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ribavirin and lethal mutagenesis of poliovirus: molecular mechanisms, resistance and biological implications.
    Vignuzzi M; Stone JK; Andino R
    Virus Res; 2005 Feb; 107(2):173-81. PubMed ID: 15649563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. D-5-Chloro-2-(alpha-hydroxybenzyl) benzimidazole and 1-alkyl-5-chloro-2-(alpha-hydroxybenzyl) benzimidazoles as inhibitors of poliovirus multiplication.
    O'Sullivan DG; Pantic D; Wallis AK
    Experientia; 1968 Jul; 24(7):661-3. PubMed ID: 4303116
    [No Abstract]   [Full Text] [Related]  

  • 20. Patterns of cytopathology and lysosomal enzyme release in poliovirus-infected HEp-2 cells treated with either 2-(alpha-hydroxybenzyl)-benzimidazole or guanidine HCl.
    Guskey LE; Smith PC; Wolff DA
    J Gen Virol; 1970 Jan; 6(1):151-61. PubMed ID: 4313397
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.